Racial differences in the treatment and outcomes for prostate cancer in Massachusetts

被引:18
|
作者
Cole, Alexander P. [1 ,2 ]
Herzog, Peter [1 ,2 ]
Iyer, Hari S. [3 ,4 ]
Marchese, Maya [1 ,2 ]
Mahal, Brandon A. [5 ]
Lipsitz, Stuart R. [2 ,6 ]
Nyambose, Joshua [7 ]
Gershman, Susan T. [7 ]
Kennedy, Mark [8 ]
Merriam, Gail [7 ]
Rebbeck, Timothy R. [3 ,4 ]
Trinh, Quoc-Dien [1 ,2 ]
机构
[1] Harvard Med Sch, Brigham & Womens Hosp, Div Urol Surg, 45 Francis St,ASB II-3, Boston, MA 02115 USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02115 USA
[4] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA
[5] Harvard Med Sch, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA
[6] Harvard Med Sch, Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA
[7] Massachusetts Dept Publ Hlth, Boston, MA USA
[8] Boston Publ Hlth Commiss, Boston, MA USA
基金
美国国家卫生研究院;
关键词
prostate cancer; racial disparities; surgical outcomes; RADICAL PROSTATECTOMY; AFRICAN-AMERICAN; UNITED-STATES; DISPARITIES; RISK; RACE; CARE; MORTALITY; SURVIVAL; MEN;
D O I
10.1002/cncr.33564
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Massachusetts is a northeastern state with universally mandated health insurance since 2006. Although Black men have generally worse prostate cancer outcomes, emerging data suggest that they may experience equivalent outcomes within a fully insured system. In this setting, the authors analyzed treatments and outcomes of non-Hispanic White and Black men in Massachusetts. Methods White and Black men who were 20 years old or older and had been diagnosed with localized intermediate- or high-risk nonmetastatic prostate cancer in 2004-2015 were identified in the Massachusetts Cancer Registry. Adjusted logistic regression models were used to assess predictors of definitive therapy. Adjusted and unadjusted survival models compared cancer-specific mortality. Interaction terms were then used to assess whether the effect of race varied between counties. Results A total of 20,856 men were identified. Of these, 19,287 (92.5%) were White. There were significant county-level differences in the odds of receiving definitive therapy and survival. Survival was worse for those with high-risk cancer (adjusted hazard ratio [HR], 1.50; 95% CI, 1.4-1.60) and those with public insurance (adjusted HR for Medicaid, 1.69; 95% CI, 1.38-2.07; adjusted HR for Medicare, 1.2; 95% CI, 1.14-1.35). Black men were less likely to receive definitive therapy (adjusted odds ratio, 0.78; 95% CI, 0.74-0.83) but had a 17% lower cancer-specific mortality (adjusted HR, 0.83; 95% CI, 0.7-0.99). Conclusions Despite lower odds of definitive treatment, Black men experience decreased cancer-specific mortality in comparison with White men in Massachusetts. These data support the growing body of research showing that Black men may achieve outcomes equivalent to or even better than those of White men within the context of a well-insured population. Lay Summary There is a growing body of evidence showing that the excess risk of death among Black men with prostate cancer may be caused by disparities in access to care, with few or no disparities seen in universally insured health systems such as the Veterans Affairs and US Military Health System. Therefore, the authors sought to assess racial disparities in prostate cancer in Massachusetts, which was the earliest US state to mandate universal insurance coverage (in 2006). Despite lower odds of definitive treatment, Black men with prostate cancer experience reduced cancer-specific mortality in comparison with White men in Massachusetts. These data support the growing body of research showing that Black men may achieve outcomes equivalent to or even better than those of White men within the context of a well-insured population.
引用
收藏
页码:2714 / 2723
页数:10
相关论文
共 50 条
  • [31] Racial Differences in Cancer Specialist Consultation, Treatment, and Outcomes for Locoregional Pancreatic Adenocarcinoma
    Melissa M. Murphy
    Jessica P. Simons
    Sing Chau Ng
    Theodore P. McDade
    Jillian K. Smith
    Shimul A. Shah
    Zheng Zhou
    Craig C. Earle
    Jennifer F. Tseng
    Annals of Surgical Oncology, 2009, 16 : 2968 - 2977
  • [32] Racial Differences in Treatment and Outcomes Among Patients With Early Stage Bladder Cancer
    Hollenbeck, Brent K.
    Dunn, Rodney L.
    Ye, Zaojun
    Hollingsworth, John M.
    Lee, Cheryl T.
    Birkmeyer, John D.
    CANCER, 2010, 116 (01) : 50 - 56
  • [33] RACIAL DIFFERENCES IN TREATMENT AND OUTCOMES AMONG PATIENTS WITH EARLY STAGE BLADDER CANCER
    Hollingsworth, John M., III
    Dunn, Rodney L.
    Ye, Zaojun
    Hollenbeck, Brent K.
    JOURNAL OF UROLOGY, 2009, 181 (04): : 690 - 690
  • [34] Racial/ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer
    Johnson, TK
    Gilliland, FD
    Hoffman, RM
    Deapen, D
    Penson, DF
    Stanford, JL
    Albertsen, PC
    Hamilton, AS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (20) : 4193 - 4201
  • [35] Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer
    Godley, PA
    Schenck, AP
    Amamoo, MA
    Schoenbach, VJ
    Peacock, S
    Manning, M
    Symons, M
    Talcott, JA
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (22): : 1702 - 1710
  • [36] Racial differences in β- and γ-catenin methylation status in prostate cancer
    Bassett, WW
    Shiina, H
    Anast, JW
    Pookot, D
    Igawa, M
    Tabatabai, ZL
    Kane, CJ
    Carroll, PR
    Dahiya, R
    JOURNAL OF UROLOGY, 2004, 171 (04): : 112 - 113
  • [37] Re: Explaining Racial Differences in Prostate Cancer Mortality
    Penson, David F.
    JOURNAL OF UROLOGY, 2013, 189 (06): : 2109 - 2110
  • [38] Racial differences in the systemic inflammatory response to prostate cancer
    Rundle, Andrew G.
    Sadasivan, Sudha M.
    Chitale, Dhananjay A.
    Gupta, Nilesh S.
    Williamson, Sean R.
    Kryvenko, Oleksandr N.
    Chen, Yalei
    Bobbitt, Kevin
    Tang, Deliang
    Rybicki, Benjamin A.
    PLOS ONE, 2021, 16 (07):
  • [39] Racial/ethnic differences in prostate cancer genomic alterations
    Dobi, Albert
    Petrovics, Gyorgy
    Tan, Shyh-Han
    Li, Hua
    Young, Denise
    Schafer, Cara
    Fox, Jesse
    Babcock, Kevin
    Hu, Heng-Cheng
    Sukumar, Gauthaman
    Song, Yingjie
    Ravindranath, Lakshmi
    Chen, Yongmei
    Cheng, Joseph
    Ebner, Reinhard
    Xiao, Qingyu
    Sun, Yidi
    Li, Yixue
    Ji, Yuan
    Hou, Jun
    Wang, Wendy
    Zhao, Guo-Ping
    Kagan, Jacob
    Srivastava, Sudhir
    Moncur, Joel T.
    Dalgard, Clifton L.
    Wilkerson, Matthew
    Rosner, Inger L.
    Cullen, Jennifer
    Freedman, Matthew
    Szallasi, Zoltan
    Sesterhenn, Isabell A.
    Srivastava, Shiv
    CANCER RESEARCH, 2018, 78 (13)
  • [40] Factors responsible for the racial differences in prostate cancer mortality
    Tewari, A
    Demers, R
    Crawford, ED
    Gamito, EJ
    Divine, G
    Johnson, CC
    Menon, M
    JOURNAL OF UROLOGY, 2003, 169 (04): : 32 - 32